Vertex Pharmaceuticals Inc. is set to report second-quarter earnings after the market close Monday, with results arriving just weeks after the biotech giant announced a $10 billion acquisition that marks its boldest diversification bet yet.
stock
Be The Investor Research
Read Original Source (Investing)
Vertex faces earnings test as $10B Crinetics deal looms
Vertex Pharmaceuticals Inc. is set to report second-quarter earnings after the market close Monday, with results arriving just weeks after the biotech giant announced a $10 billion acquisition that marks its boldest diversification bet yet.